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Abstract
The development of processes to produce biopharmaceuticals industrially is still largely empirical and relies on optimizing
both medium formulation and cell line in a product-specific manner. Current small-scale (well plate-based) process
development methods cannot provide sufficient sample volume for analysis, to obtain information on nutrient utilization
which can be problematic when processes are scaled to industrial fermenters. We envision a platform where essential
metabolites can be monitored non-invasively and in real time in an ultra-low volume assay in order to provide additional
information on cellular metabolism in high throughput screens. Towards this end, we have developed a model system of
Chinese Hamster Ovary cells stably expressing protein-based biosensors for glucose and glutamine. Herein, we demonstrate
that these can accurately reflect changing intracellular metabolite concentrations in vivo during batch and fed-batch culture
of CHO cells. The ability to monitor intracellular depletion of essential nutrients in high throughput will allow rapid
development of improved bioprocesses.
Citation: Behjousiar A, Kontoravdi C, Polizzi KM (2012) In Situ Monitoring of Intracellular Glucose and Glutamine in CHO Cell Culture. PLoS ONE 7(4): e34512.
doi:10.1371/journal.pone.0034512
Editor: Jonathan A. Coles, Glasgow University, United Kingdom
Received January 23, 2012; Accepted March 6, 2012; Published April 3, 2012
Copyright:  2012 Behjousiar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: AB would like to thank the Biotechnology and Biological Sciences Research Council for his studentship. KMP and CK are supported by Research
Councils United Kingdom fellowships. CK thanks LONZA Biologics for their financial support. The Centre for Synthetic Biology and Innovation is supported by the
Engineering and Physical Sciences Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: CK holds a research fellowship that is funded in part by LONZA Biologics. They were not involved in the work presented in this
publication. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: k.polizzi@imperial.ac.uk
Introduction
Biopharmaceuticals, or protein-based drugs, are the fastest
growing class of therapeutics with over 500 new molecules
currently in development [1] annual sales of more than $90
billion USD in 2009 [2]. Approximately 70% of these molecules
are glycoproteins [1]. The development of industrial processes for
biopharmaceutical production is a slow and expensive process
which involves the generation and maintenance of hundreds of cell
lines which are assessed for the ability to produce high levels of
high quality product at various scales and the optimisation of
cellular growth medium to boost production levels and ensure
consistent glycosylation patterns. Process development remains
largely an empirical exercise as we have yet to establish a full
understanding of the mechanistic link between process conditions/
medium formulation, cellular metabolism, and product formation
rates. Efforts at high throughput process development are
currently hampered by a lack of information-rich assays on the
small scale. Assessment of cell growth in small volumes by solely
estimating confluence cannot be predictive of behaviour in
industrial-scale fermenters [3]. Therefore, significant effort
towards the development of miniaturized analytical devices to
detect important metabolites in cell culture is currently underway.
Many solutions now exist for detecting extracellular concentra-
tions of metabolites using chemical (e.g. [4]), enzymatic (e.g. [5]), or
binding protein-based assays (e.g. [6]).
A significant improvement to current practice would be the
development of a system that offers the ability to monitor essential
intracellular metabolite utilization rates in situ, non-destructively
and in small volumes so this information could be incorporated
earlier in process development. Fo¨rster resonance energy transfer
(FRET) biosensors based on fluorescent proteins offer the
possibility to measure metabolic functions in vivo and can form
the basis of a platform for non-invasive cell culture monitoring.
FRET biosensors have previously been used to monitor individual
metabolites (e.g. [7–9]), track multiple targets [10], as well as to
provide spatiotemporal information at the subcellular level [11].
In this paper, we report the development of a CHO cell culture
system expressing protein-based biosensors for glucose and
glutamine and present data for in vitro and in vivo calibration of
their fluorescent signal. We further evaluate how other amino
acids present intracellularly can compete with glutamine for the
ligand binding site of the glutamine biosensor and, thus, interfere
with the signal emitted by this biosensor and at which
concentrations this adverse effect occurs. Finally, we assess how
this system can be used in-process in batch and fed-batch cell
cultures for obtaining data for intracellular concentrations of these
two key nutrients. This constitutes a proof-of-principle for this in
situ monitoring platform, which can be extended in the future to
other vital metabolites. Such an approach would remove
uncertainties arising from the choice of quenching and extraction
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methods, obviate the need for destructive sampling, and could
provide real-time information for in-process decision making.
Materials and Methods
Cell line maintenance
CHO cells (CHO-S from Invitrogen, UK) were maintained in
suspension in CD-CHO medium (which contains 36 mM glucose
and 0 mM L-glutamine, Invitrogen, UK, Catalogue number:
10743-029) supplemented with 8 mM L-Glutamine and 10 ml/L
1006 hypoxanthine/thymidine supplement (Invitrogen, UK,
Catalogue number: 11067-030). The cells were subcultured every
3–4 days with a seeding density of 26105 cells mL21 and were
grown in 250 mL Erlenmeyer flasks in a working volume of
50 mL. They were kept in a cell incubator at 37uC, a humidified
atmosphere of 5% CO2, on an orbital shaking platform rotating at
125 rpm.
FRET sensor plasmid construction and transfection
The glucose FRET plasmid pRSET-FLIPglu600mD11Aphro-
dite (Addgene number 13569) was kindly supplied by Professor
Wolf Frommer (Carnegie Institution for Science, Stanford
University) and transformed directly into chemically competent
E coli BL21(DE3) Gold cells (Agilent, UK) for protein production.
FLIPglu600mD11Aphrodite is a fusion of the enhanced cyan
fluorescent protein (ECFP) and the Aphrodite variant of the
enhanced yellow fluorescent protein (EYFP) to the F16A mutant of
the E.coli glucose/galactose periplasmic binding protein (mglB). 11
amino acid residues were deleted in the linker region to optimise
the FRET efficiency [12]. To construct the mammalian expression
plasmid, the FLIPglu600mD11Aphrodite gene was PCR amplified
from the original vector and cloned into the pCDNA4/TO vector
(Invitrogen, UK) using the unique EcoRI and PstI restriction sites.
The glutamine FRET construct in the pUTKan plant
expression vector was kindly supplied by Dr Uwe Ludewig
(Hohenheim University). The biosensor is based on an insertion of
the yellow fluorescent protein citrine into the E.coli glutamine
periplasmic binding protein (QBP) between amino acids 98 and 99
with the ECFP attached to the C-terminus. Several additional
residues in the linking region were deleted in order to rigidify the
linker structure. The amino acid substitution D157N has been
made to the QBP to increase affinity for glutamine and several
mutations have been incorporated to improve FRET efficiency
[9]. The vector supplied was digested with BamHI and SalI to
release the insert which was subsequently cloned into the
corresponding restriction sites in the vector pET41a in frame
with the N-terminal purification tags. This was then transformed
into competent BL21(DE3) Gold E.coli cells (Agilent, UK) for
protein expression The mammalian expression vector was created
by ligating the same insert into the pCDNA4/TO vector which
had been digested with BamHI and XhoI, taking advantage of the
compatible sticky ends produced by SalI and XhoI.
The mammalian expression vectors containing the glucose and
glutamine FRET sensors were transfected into CHO cells using
the TransIT-ProTM transfection kit (Mirus Bio) according to the
manufacturer’s protocol. Stable transfectants were selected using
400 mg/mL Zeocin (Invivogen).
Production of sensors in E. coli and protein purification
Both FRET sensor proteins were expressed in BL21(DE3) Gold
E.coli cells (Agilent, UK). For the glucose FRET sensor, a single
colony of freshly transformed cells was inoculated into a 2 L plastic
baffled flask (Nalgene), containing 500 mL LB broth supplement-
ed with 50 mg mL21 of ampicillin. The flask was incubated at
room temperature in a Thermo scientific MaxQ horizontal
shaking cabinet (225 rpm) for 2–3 days, in darkness as the
flourophores are sensitive to light. After 2–3 days the cells were
harvested by centrifugation for 15 minutes at 6000 rpm and 4uC.
For the glutamine FRET sensor, a single colony was inoculated
into a 2 L plastic baffled flask (Nalgene), containing 500 mL LB
broth supplemented with 30 mg mL21 of kanamycin. Cells were
grown for one day at room temperature with shaking at 225 rpm,
followed by the addition of IPTG to a final concentration of
0.2 mM. Cells were incubated for a further two days before
harvesting by centrifugation as above.
For affinity chromatography, cell pellets were re-suspended in
5 mL ice cold lysis buffer (20 mM Tris-Cl, pH 8.0) and transferred
to a 50 mL Falcon tube. The cells were lysed with a Sonics Vibra
Cell sonicator using pulses of 15 seconds on, 15 seconds off for
3 minutes. Samples were then centrifuged for 1 hour at 5000 rpm
to remove cell debris. The lysates were removed and 1 mL Ni-
NTA resin (Qiagen) was added per 4 mL of protein lysate. The
protein was bound to the resin for 1 K hours in a cold room,
under gentle agitation. The resin beads were packed into a
disposable plastic polypropylene column (Qiagen) and washed
with 10 mL ice cold wash buffer (20 mM Tris-Cl, pH 8.0, 10 mM
imidazole) twice at 4uC. The protein was eluted with 561 mL
addition of ice cold elution buffer (20 mM Tris-Cl, pH 8.0,
500 mM imidazole). To obtain the highest concentrations of
protein, the eluate was collected in 5 separate fractions. For the
glucose sensor, the three most concentrated protein samples were
injected into a Slide-a-LyzerH dialysis cassette (Membrane
Molecular weight cut-off 20.000 Da) and dialysed overnight
against 50 mM sodium phosphate buffer pH 7.0 at 4uC to remove
the imidazole. Dialysis caused the glutamine biosensor to
precipitate, so this was used as eluted from the IMAC column.
Protein concentrations were measured using a Nanodrop 1000
(Thermo Scientific) using an appropriate blanking solution.
Proteins were stored overnight at 4uC before fluorescence
measurements were taken.
Batch and fed-batch CHO cell cultures
Batch overgrow cell cultures were maintained in duplicates for
11 days in 250 ml Erlenmeyer flasks with a working volume of
50 ml. Samples were removed at 24 h-intervals to determine the
viable cell concentration by light microscopy using the trypan blue
dye exclusion method. Additional samples for intracellular
metabolite analysis were removed for metabolite extraction. These
were handled on ice at all times to slow metabolism [13] and
minimize metabolite loss. Samples were centrifuged at 800 rpm
for 5 minutes at 4uC and the supernatant was removed. The pellet
was re-suspended in 3 ml ice cold phosphate buffered saline (PBS)
and centrifuged for 5 minutes at 800 rpm at 4uC as a wash step.
The supernatant was again removed and the pellet was re-
suspended in ice cold PBS as above. This was then sonicated on
ice (Sonics, vibra cell) a total of 5 times for 3 minutes each at a
pulse of 15 seconds on and 15 seconds off. Directly after
sonication the cell extracts were frozen at 220uC. Fed batch
experiments were conducted in duplicates as with the batch
overgrow experiments in 250 mL of CD-CHO but with additional
supplementation of glucose or glutamine on day 6 of the cell
culture to bring the extracellular concentrations of these
metabolites to 36 mM and 4 mM, respectively. Alongside these
cultures, we maintained two control cultures that were fed with the
same volume of pure water instead of nutrients.
In Situ Monitoring of CHO Cell Culture
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Metabolite assays
The intracellular concentrations of metabolites were determined
enzymatically using cell extracts following sonication. To prevent
destruction of metabolites during the measurement process, cell
extracts were handled on ice at all times. Intracellular concentra-
tions of glucose were determined using the Amplex H Red Glucose
Assay kit (Invitrogen, UK) according to the manufacturer’s
instructions. Briefly, this is a coupled enzyme assay which relies
on glucose oxidase to convert the glucose to gluconolactone plus
hydrogen peroxide and horseradish peroxidase to react the
hydrogen peroxide with the Amplex H Red reagent to produce a
product which is both fluorescent and coloured. In our case,
glucose concentrations were determined by monitoring an
increase in absorbance at 560 nm compared to a standard curve
of known concentrations. Intracellular concentrations of glutamine
were determined using the EnzyChrom Glutamine Assay kit
(Universal Biologics), a coupled glutaminase/glutamate dehydro-
genase assay that produces a colourimetric response at 565 nm.
Concentrations were determined by comparison to a standard
curve with correction for the presence of intracellular glutamate as
recommended in the manufacturer’s instructions. The metabolite
concentrations from the assays were converted to intracellular
concentrations using a CHO cell diameter of 12 mm [14].
Fluorescence measurements and FRET ratio calculations
All fluorescence measurements were made in a Tecan Infinite
200Pro fluorescence plate reader using an excitation wavelength of
430/35 nm and emission wavelengths of 465/35 nm (blue) and
520/10 nm (yellow). In vitro calibration curves were determined
using purified protein at a final concentration of 0.3–0.5 mg/mL
in phosphate buffered saline pH 7.2 using increasing concentra-
tions of ligand. For glucose, concentrations ranged from 10 mM to
1 M, while for glutamine concentrations ranged from 50 mM to
80 mM. For each concentration, FRET ratios were calculated as
the amount of yellow fluorescence detected divided by the amount
of blue fluorescence detected after correction for the background
fluorescence of a sample containing no protein. The FRET ratios
obtained were compared with the published literature for previous
use of the biosensors as a benchmark [9,12]. Competition assays
for the glutamine biosensor were conducted using purified protein
and 1 mM glutamine supplemented with the maximum intracel-
lular concentrations of each of the other amino acids reached at
any point during batch cell culture from data reported in other
studies (Table 1, [15]). In vivo fluorescence measurements were
performed using cells sampled from a growing flask into a 6 well
plate. Every 24 hours, a 2 mL sample was removed from the flask
and pelleted by centrifugation at 800 rpm for 5 minutes at 4uC.
The cell pellet was resuspended in 2 mL of ice cold PBS and
pipetted into a 6 well plate. Blue and yellow fluorescence
measurements were made immediately. A small part of the
sample was then used for viable cell concentration determination
using the trypan blue exclusion method and the rest of the sample
sonicated as described in the metabolite assay section above. The
FRET ratios were calculated as the amount of yellow fluorescence
detected divided by the amount of blue fluorescence detected.
Results and Discussion
Biosensor selection
Intracellular metabolite data determined enzymatically from
initial CHO cell cultures were used to determine the range of
glucose and glutamine concentrations that occur over the lifetime
of a batch overgrow experiment (Figures 1a and 1b) and,
ultimately, to select biosensors with appropriate measurement
ranges. Intracellular concentrations of glucose are very high in the
first few days of cell culture, but steadily decrease over time,
reaching a low of approximately 400 mM on days 5 and 6 of
culture. This coincides with the peak in cell number (data not
shown). During the stationary and decline phase, intracellular
glucose concentrations increase again. Overall, with the exception
of the early days of cell culture, average intracellular glucose
concentrations range from 0.4 mM to 6 mM. In contrast, the
levels of glutamine remain low and comparable across the lifetime
of the cell culture, varying only between approximately 0.4 and
1 mM. Based on these concentration ranges, the biosensors
FLIPglu600mD11Aphrodite [12] and the D157N variant of the
QBP [9] were selected from the literature as having a linear range
of measurement that corresponds with the intracellular metabolite
concentrations measured. These two biosensors both work on the
principle of FRET between fluorophores of the blue and yellow
wavelength, but show opposite trends with respect to metabolite
concentration (Figure 2). In the case of the glucose biosensor,
binding of glucose causes a disruption of the fluorophore
alignment, resulting in a decrease in FRET, whereas in the case
of the glutamine biosensor, binding of glutamine causes the
fluorophores to move into closer proximity, resulting in an
increase in FRET.
In vitro calibration
In order to verify the linear range of measurement, the
biosensors were overexpressed in E coli and the histidine tagged
protein purified using immobilised metal affinity chromatography.
Purified protein was then titrated against different concentrations
of ligand and the results compared against published values as a
benchmark (Figures 3a and b). Overall, our measured FRET
ratios were in close agreement with those previously reported and
Table 1. Concentrations of amino acids used in the
competition study.
Amino Acid Range
Concentration
Used Reference
Alanine 9.4–10.7 mM 10 mM Hansen and Emborg, 1994
Arginine 0–2.3 mM 3 mM Hansen and Emborg, 1994
Asparginine 0.04–18.7 mM 20 mM Hansen and Emborg, 1994
Aspartate 1.1–3.4 mM 4 mM Hansen and Emborg, 1994
Cysteinea 0.5–5 mM 5 mM CK, unpublished data
Glutamate 2.6–4.6 mM 5 mM Hansen and Emborg, 1994
Glutamine 0.3–0.9 mM 1 mM Hansen and Emborg, 1994
Glycine 4.4–8.4 mM 9 mM Hansen and Emborg, 1994
Histidine 0.3–0.6 mM 0.5 mM Hansen and Emborg, 1994
Isoleucine 0.5–0.8 mM 1 mM Hansen and Emborg, 1994
Leucine 0.2–0.5 mM 0.5 mM Hansen and Emborg, 1994
Lysine 0.2–0.6 mM 0.5 mM Hansen and Emborg, 1994
Phenylalanine 0.6–0.8 mM 1 mM Hansen and Emborg, 1994
Serine 0.5–1 mM 1 mM Hansen and Emborg, 1994
Threonine 0.9–3.5 mM 4 mM Hansen and Emborg, 1994
Tyrosine 0.03–0.5 mM 1 mM Hansen and Emborg, 1994
Valine 0.6–1.2 mM 1 mM Hansen and Emborg, 1994
aFor cysteine, the maximum extracellular concentration was used as data on
intracellular concentration was not reported and this metabolite was shown to
produce a high FRET ratio in [9].
doi:10.1371/journal.pone.0034512.t001
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the linear range of concentration measurement appears to be
preserved. However, for the glutamine biosensor, the absolute
values of our FRET ratios were consistently lower than those
reported. Since the relationship remained linear, had the same
midpoint, and appears to be directly downshifted from the values
reported by Yang et al, this suggests a systematic difference arising
Figure 1. Intracellular metabolite concentration ranges during batch overgrow CHO-S culture. a) Glucose concentration measured by
the Amplex Red H glucose oxidase assay (gray circles) and glutamine concentration measured by a coupled glutaminase, glutamate dehydrogenase
assay with correction for glutamate concentration (black squares) over the course of the batch overgrow culture. Error bars represent one standard
deviation of the mean (n = 4 flasks with three enzymatic assay samples per flask) b) A closer view of the concentration of metabolites on days 4 to 8
(exponential to early stationary phase).
doi:10.1371/journal.pone.0034512.g001
Figure 2. Diagrammatic representation of FRET sensor function. a) The glucose biosensor has maximum FRET efficiency in the absence of
ligand. The binding of glucose causes a twist in the alignment of the fluorophores which causes the FRET ratio to decrease. b) The glutamine
biosensor has maximum FRET efficiency in the presence of ligand which causes the binding domain to hinge closed, bringing the fluorophores into
closer contact.
doi:10.1371/journal.pone.0034512.g002
In Situ Monitoring of CHO Cell Culture
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Figure 3. In vitro titration data in comparison with published results. a) Glucose biosensor measurements from Deuschle et al (2005)
compared with titrations using purified protein extracted and measured as per the Materials and Methods section (n = 3 independent protein
preparations, with 3 FRET ratio measurements per ligand concentration). b) Glutamine biosensor measurements from Yang et al (2010) compared
In Situ Monitoring of CHO Cell Culture
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from our experimental apparatus. Indeed, Yang et al. used an
excitation filter of 433/12 nm and an emission filter of 475/12 nm
for their ECFP measurements, which would have experienced less
bleed through of the excitation wavelength than our filter set (430/
35 nm, 465/35 nm). This is the most likely source of the
discrepancy as our set-up would result in slightly higher blue
fluorescence measurements, systematically decreasing the FRET
ratio calculated.
In vivo calibration
FRET measurements in vivo are complicated by the fact that cell
wall constituents and macromolecules can absorb and reflect light,
leading to noise in measurements. In particular, this is a problem
with lower wavelength light. Therefore, the in vitro calibration
curves cannot be used directly to estimate the concentration of
metabolites within the cells; an in vivo calibration must also be
performed. Strangely, this step is often omitted in published work,
but is vital for quantification. We transfected the mammalian
expression plasmids into CHO cells and selected for stable
integration of the plasmid. In order to calibrate the biosensor,
we capitalised on the fact that intracellular concentrations of
glucose and glutamine vary naturally with time. Thus, by sampling
cells over the course of several days, we would be able to
benchmark against different intracellular concentrations, at the
same time ensuring that we were able to measure the range of
metabolite concentrations which would be occurring naturally
within our cell population of interest. Figure 4a shows the results of
the in vivo calibration of the glucose biosensor with simultaneous
measurements of the FRET ratio of intact cells and the
intracellular glucose concentration (measured in cell extracts
sampled from the same cultures at the same time as the FRET
ratio was measured). FRET measurements before day 4 of the cell
culture were subject to a high degree of variability due to low cell
numbers, and after day 8 the presence of a significant number of
lysed cells results in a high amount of light scattering (data not
shown). Thus, the graph shows only the results for days 4 to 8.
Figure 4b displays the same data as a calibration curve. The high
R-squared value for the calibration curve indicates a high degree
of correlation between the FRET measurements and the
intracellular glucose concentration.
Figures 4c and 4d show the corresponding measurements for
glutamine. In the case of the glutamine biosensor, the degree of fit
is lower than that for the glucose biosensor, possibly due to
interference by other amino acids as analysed in the section below.
However, the calibration curve provides a means of determining
the intracellular concentration range of glutamine with some
degree of accuracy nonetheless. We note that the biosensor signal
is best correlated with the intracellular concentrations between 1
and 7 mM for glucose and 0.5 and 2 mM for glutamine measured
on days 4 to 8 of a batch cell culture. Although this is a limitation,
with titrations titrations using purified protein extracted and measured as per the Materials and Methods section (n = 3 independent protein
preparations, with 3 FRET ratio measurements per ligand concentration, error bars represent one standard deviation of the mean). Inset depicts a
zoomed in view of the lower concentrations of glutamine.
doi:10.1371/journal.pone.0034512.g003
Figure 4. In vivo calibration curves. A comparison of the FRET measurements obtained from stable CHO-S cell lines constitutively expressing the
biosensors and the corresponding measurements of intracellular concentrations from the same samples. a) Glucose biosensor measurements.
Intracellular concentration as measured by the Amplex Red H assay (gray circles) and corresponding FRET measurements (black squares). b) FRET
versus concentration calibration curve for the glucose biosensor. The line represents the linear regression best fit for the data points. c) Glutamine
biosensor measurements. Intracellular concentration as measured by the coupled glutaminase glutamate dehydrogenase assay (gray circles) and
corresponding FRET measurements (black squares). d) FRET versus concentration calibration curve for the glutamine biosensor. The line represents
the linear regression best fit for the data points. In all cases, n = 2 biological repeats with three measurements per cell line. Error bars represent one
standard deviation of the mean.
doi:10.1371/journal.pone.0034512.g004
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these days correspond to the exponential, stationary, and early
decline phases of cell culture, which are the most important to
understand for bioprocess development. Additionally, other
operational modes, such as fed-batch (see below) or continuous
cultures would have a longer viable period of measurement, due to
sustained high viability and cell concentration.
Amino acid interference study
The mglB protein upon which the glucose biosensor is based has
a well known substrate specificity and has been demonstrated to
bind glucose and galactose with approximately equal affinity [16]
with very low affinity for other sugars [17]. Given the significantly
low galactose uptake rates compared in industrial CHO cell
culture even when it is the sole carbon source, i.e. in the absence of
glucose [18], we felt that the glucose biosensor would not be
subjected to interference by other metabolites in our experimental
set up.
On the other hand, very little data exist on the ability of the
glutamine binding protein to bind other amino acids. Previous
work indicated that the glutamine biosensor was also able to bind
to other amino acids and produce a FRET signal [9]. In
particular, they noticed large positive FRET ratio changes upon
addition of millimolar levels of arginine, cysteine, and histidine
and negative FRET ratios produced in response to aspartate,
glutamate and lysine, when adding individual amino acids to the
purified protein. However, for use in vivo what is more relevant is
whether physiogically relevant levels of amino acids interfere with
the ability of glutamine to enter the ligand binding domain, i.e.
whether the addition of amino acids at the levels normally
encountered within CHO cells in culture will affect our ability to
measure glutamine concentration. For example, in the presence of
glutamine, do arginine and cysteine still bind, or is glutamine
preferred? Will any of the other amino acids prevent glutamine
entering the active site even if they themselves do not produce a
FRET signal? In batch and fed-batch cell cultures amino acid
levels vary across culture time as some amino acids supplemented
in the medium are depleted and other amino acids are synthesised
as a result of metabolic activity. If any of these interfere with the
signal of the biosensor in response to glutamine, this would create
difficulties in utilising the sensor as the interference would be time-
dependent and thus very difficult to correct for.
Therefore, we tested whether the maximum concentration of
amino acid encountered during the course of cell culture (as
reported in Hansen and Emborg [15], Table 1) affected our ability
to measure glutamine concentration accurately by adding
individual amino acids to the purified protein in the presence of
glutamine. Overall, most amino acids do not affect the ability of
the biosensor to measure glutamine concentration accurately
(Figure 5). In fact, the maximum difference in the measured FRET
ratio change is approximately 20%, suggesting the level of
interference is low. Interestingly, of the amino acids reported to
bind to the biosensor and produce an increase in FRET in Yang et
al, only cysteine produces a measurably higher change in FRET
ratio when analysed in this context. Even asparginine, which is
highly structurally similar to glutamine, does not produce a high
level of interference. In addition to lower FRET ratios for
aspartate and glutamate as reported, we also found decreased
FRET ratio changes for glycine, threonine, valine, and tyrosine,
indicating that these amino acids interfere with the ability of
glutamine to bind to the active site of the protein when they are
present. Glycine, threonine, and valine are relatively small amino
acids and so could potentially enter the binding pocket of the
biosensor and prevent glutamine access even if they themselves are
not able to cause the conformational change necessary to produce
Figure 5. Assessment of the competition of other amino acids for the glutamine binding protein in the glutamine biosensor. The
ability of the purified biosensor protein to accurately report the concentration of glutamine in the presence of other amino acids was measured using
the maximum intracellular concentration of amino acid encountered during cell culture and 1 mM glutamine. Results are plotted as the change in
FRET ratio between each condition and the FRET ratio of the purified biosensor with no ligand present. n = 3. Error bars represent one standard
deviation of the mean.
doi:10.1371/journal.pone.0034512.g005
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a FRET ratio change. Taken together, these results suggest that
the error in our ability to measure glutamine concentration is fairly
low. This can be investigated further in situations where higher
amino acid concentrations are anticipated due to the addition of
complex feeds, even though a higher amino acid uptake rate may
not necessarily result in higher intracellular concentrations but
rather a higher metabolic activity and incorporation into proteins.
Fed-batch culture results
In order to demonstrate that the two biosensors function in a
bioprocessing context, we employed them for a study of fed-batch
CHO cell cultures. Fed-batch culture is an operation mode
whereby batch cultures are supplemented with additional nutrients
later in cell culture in order to sustain cell viability and increase the
culture lifetime and protein production. In this case, the cells were
fed on day 6 of culture with a bolus addition of glucose and
glutamine stock solution sufficient to bring the nutrient concen-
tration up to36 mM for glucose and 4 mM for glutamine.
Figures 6a and b compare the responses of the biosensor for cells
that were fed versus those that were given a similar volume of pure
water. The glucose biosensor has an inverse relationship between
FRET and glucose concentration. Thus, one would expect that
cells which had been fed glucose would show a significantly lower
FRET ratio due to an increase in intracellular glucose concentra-
tion. Indeed, Figure 6a shows that this is the case: on day 7, cells
that had been fed additional glucose have a FRET ratio that is less
than one half of the ratio we obtained for the unfed control
cultures. For the glutamine biosensor, increased glutamine
concentration brings an increase in FRET, so addition of feed
should result in an increased FRET ratio. Figure 6b shows that this
is also the case, as the FRET ratio on day 7 is about 4 times higher
in cells which were fed additional glutamine.
Conclusions
We have demonstrated the utility of in vivo biosensors based on
Fo¨rster Resonance Energy Transfer (FRET) for non-invasively
monitoring the intracellular concentrations of primary metabolites
in the batch and fed-batch cultivation of CHO cells. As a proof-of-
principle, we chose to track two of the most important metabolites
in mammalian bioprocessing: glucose, which acts as a primary
energy source and carbon skeleton donor, and glutamine, which
serves as an energy and nitrogen source. However, the
methodology could be extended to monitoring other small
molecules of interest and to other cell lines. In addition, while
both of our biosensors use the blue and yellow fluorescent
chromophores and so at present are mutually exclusive, strategies
have been developed for simultaneously monitoring multiple
targets using FRET pairs of different colours [10].
We selected the biosensors based on their ability to assess
concentrations with a linear range of measurement that corre-
sponds to the intracellular concentrations of glucose and glutamine
encountered in cell culture and created stable cell lines that express
the biosensor construct. Through simultaneous measurement of
metabolite concentration and FRET ratio we were able to
Figure 6. Fed batch culture of CHO-S cells and corresponding FRET measurements. a) Glucose fed-batch monitoring. Comparison of cells
fed with glucose on day 6 (gray circles) and those given an equal volume of pure water (black squares). Arrow indicates addition of bolus feed to
bring glucose concentration to 36 mM. b) Glutamine fed-batch monitoring. Comparison of cells fed with glutamine on day 6 (gray circles) and those
given an equal volume of pure water (black squares). Arrow indicates addition of bolus feed to bring glutamine concentration to 4 mM. n= 3. Error
bars represent one standard deviation of the mean.
doi:10.1371/journal.pone.0034512.g006
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construct a calibration curve that can be used to accurately
determine intracellular metabolite concentrations in situ without
the need for quenching and metabolite extraction. We have
further demonstrated that the acquired FRET ratio is subject to
only minor alterations due to the presence of other metabolites,
such as amino acids other than glutamine, and is therefore a
reliable means for in vivo monitoring.
Importantly, the results demonstrate that the sensors would be
useful in a bioprocessing context as we are able to get robust
measurements of the intracellular concentrations of metabolites
using cell sampling and a basic fluorescent plate reader, as
opposed to requiring more sophisticated equipment such as a
confocal microscope. This would allow for rapid data collection as
well as open up the possibility of small scale screening assays for
medium formulation and/or cell line engineering. Moreover,
there is the possibility in the future to grow cells directly in the well
plate and measure metabolite concentrations online, in situ in a
low-volume, high throughput assay which would significantly
speed up process development.
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